Current and future options for treatment of osteoporosis
Authors:
J. Blahoš
Authors place of work:
Oddělení klinické endokrinologie a Osteocentrum ÚVN Praha, vedoucí prof. MUDr. Jaroslav Blahoš, DrSc.
Published in the journal:
Vnitř Lék 2011; 57(11): 888-890
Category:
Birthday
Summary
The author describes actual and perspective treatment of osteoporosis. Basic treatment consists in calcium, vitamin D, physical activity, restriction of risk factors and prevention of falls. Actual treatment includes antiresorptive drugs (calcitonin, bisphosphonates, estrogens and SERM) and denosumab. Perspective emerging drugs are also mentioned.
Key words:
osteoporosis – actual and emerging treatment
Zdroje
1. Blahoš J. Treatment and prevention of osteoporosis. Wien Med Wochenschr 2007; 157: 589–592.
2. Vyskočil V. Osteoporóza a ostatní nejčastější metabolická onemocnění skeletu. Praha: Galén 2009.
3. Skácelová S. Denosumab. Remedia 2011; 3: 230–237.
4. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377: 1276–1287.
5. Stroup GB, Lark MW, Veber DF et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 2011; 16: 1739–1746.
6. Pathi D, Stouch B, Jang G et al. Antisklerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res 2007; 22: 537–545.
7. Cirmanová V, Stárka L. Sklerostin – nový regulační marker kostního obratu a klíčový cíl v terapii osteoporózy. Osteol Bull 2011; 1: 16–19.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2011 Číslo 11
Najčítanejšie v tomto čísle
- Antibiotic treatment of acute bacterial infections
- Management of obesity – options, effectiveness and perspectives
- Genetics of monogenic forms of diabetes
- Modern technologies in diabetology. CSII (Continuous Subcutaneous Insulin Infusion) and CGM (Continuous Glucose Monitoring) in clinical practice